On June 3, 2021 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, reported that the results from the Phase II MARCH trial of selinexor plus low dose dexamethasone (the Sd regimen) for the treatment of Chinese patients with relapsed or refractory multiple myeloma (RRMM) are published at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the 2021 European Hematology Association (EHA) (Free EHA Whitepaper) Virtual Congress (Press release, Antengene, JUN 3, 2021, View Source [SID1234583485]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data from a planned analysis of the first 60 treated patients with a median follow-up of 9.5 months demonstrates an overall response rate (ORR) of 26.7%. Meanwhile, an ORR of 33.3% was achieved with the Sd regimen in triple-class-exposed (IMiDs, PIs and anti-CD38 mAb) patients, and an ORR of 44.4% was achieved in patients that previously received CAR-T therapies. In Chinese patients that were refractory to both immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), results from the MARCH trial have confirmed the efficacy and manageable safety profile of the Sd regimen, which is consistent with that observed in the STORM trial, the data from which supported the accelerated approval of selinexor by the U.S. Food and Drug Administration (FDA).
Selinexor, the first-in-class XPO1 inhibitor approved for the treatment of RRMM and relapsed or refractory diffuse large B-cell lymphoma (RRDLBCL), has five regimens added to the National Comprehensive Cancer Network (NCCN) Guidelines and four regimens added to the Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines. Antengene has submitted new drug applications (NDAs) for selinexor in five APAC markets and anticipates receiving approvals for these NDAs in Q4 2021 and Q1 2022.
ASCO 2021 Annual Meeting
The full abstract is now available at:
Abstract Title:
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
Abstract #: e20002
EHA2021 Virtual Congress
The full abstract is now available at:
Abstract Title:
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
Abstract #: PB1670